Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:SPPI

Spectrum Pharmaceuticals (SPPI) Stock Price, News & Analysis

Spectrum Pharmaceuticals logo

About Spectrum Pharmaceuticals Stock (NASDAQ:SPPI)

Key Stats

Today's Range
$1.03
$1.03
50-Day Range
$0.94
$1.03
52-Week Range
$0.32
$1.57
Volume
N/A
Average Volume
1.93 million shs
Market Capitalization
$211.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.

Receive SPPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPPI Stock News Headlines

When it comes to NVDA… “acceleration cycles” are the key
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.
See More Headlines

SPPI Stock Analysis - Frequently Asked Questions

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) issued its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.07.

Based on aggregate information from My MarketBeat watchlists, some other companies that Spectrum Pharmaceuticals investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Globant (GLOB), Toast (TOST), Ginkgo Bioworks (DNA) and NOVONIX (NVNXF).

Company Calendar

Last Earnings
11/10/2021
Today
11/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SPPI
CUSIP
84763A10
Employees
86
Year Founded
2002

Profitability

Net Income
$-75,400,000.00
Pretax Margin
-263.04%

Debt

Sales & Book Value

Annual Sales
$10.11 million
Book Value
$0.15 per share

Miscellaneous

Free Float
199,704,000
Market Cap
$211.41 million
Optionable
Optionable
Beta
2.15

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

This page (NASDAQ:SPPI) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners